Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...
Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...
An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
ZME Science on MSN
Inside the Human Gene Editing Boom Driven by CRISPR Reshaping Everything From Medicine to Food
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based ...
CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its ...
According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...
The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...
A single infusion of CRISPR Therapeutics' experimental gene therapy was safe and reduced levels of harmful LDL cholesterol ...
The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback